Avsnitt
-
Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2–ultra-low breast cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001338.
The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
Prevalence of "HER2 Ultra-Low" Among Patients With Advanced Breast Cancer With Historical IHC0 Status https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13156
Targeting HER2-Positive Breast Cancer: Advances and Future Directions https://pubmed.ncbi.nlm.nih.gov/36344672/
Are There More HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients With HER2 Negative Immunohistochemistry https://pubmed.ncbi.nlm.nih.gov/37936021/
Trastuzumab Deruxtecan (T-DXd) vs Physician's Choice of Chemotherapy (TPC) in Patients (Pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (MBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06) https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1000
The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37303241/
Prognostic Relevance of the HER2 Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients Screened for Participation in the DETECT Study Program https://pubmed.ncbi.nlm.nih.gov/34839105/
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update https://pubmed.ncbi.nlm.nih.gov/31928404/
Adjuvant Therapy for Breast Cancer https://emedicine.medscape.com/article/1946040-overview
Tumor Infiltrating Lymphocytes (TILs) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications From Pathologist's Perspective https://pubmed.ncbi.nlm.nih.gov/37760449/
-
Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/37762027/
Pathological Identification of HER2-Low Breast Cancer: Tips, Tricks, and Troubleshooting for the Optimal Test https://pubmed.ncbi.nlm.nih.gov/37077201/
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://pubmed.ncbi.nlm.nih.gov/32954927/
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles https://pubmed.ncbi.nlm.nih.gov/38132377/
Subtypes of Breast Cancer https://www.ncbi.nlm.nih.gov/books/NBK583808/
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/
Trastuzumab Deruxtecan in Metastatic Breast Cancer With Variable HER2 Expression: The Phase 2 DAISY Trial https://pubmed.ncbi.nlm.nih.gov/37488289/
Decoding TROP2 in Breast Cancer: Significance, Clinical Implications, and Therapeutic Advancements https://pubmed.ncbi.nlm.nih.gov/37954074/
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) https://clinicaltrials.gov/study/NCT06533826
-
Saknas det avsnitt?
-
Drs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2-positive breast cancer, including the biology and management of patients.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/34208287/
Adjuvant Trastuzumab Emtansine in HER2-Positive Breast Cancer Patients With HER2-Negative Residual Invasive Disease in KATHERINE https://pubmed.ncbi.nlm.nih.gov/36117201/
Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions https://pubmed.ncbi.nlm.nih.gov/38241599/
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/33916438/
ALK-Positive Lung Cancer: A Moving Target https://pubmed.ncbi.nlm.nih.gov/36797503/
Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/35326665/
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies https://pubmed.ncbi.nlm.nih.gov/38471052/
Stereotactic Radiosurgery and Local Control of Brain Metastases From Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36433878/
Multi-institutional Validation of Brain Metastasis Velocity, a Recently Defined Predictor of Outcomes Following Stereotactic Radiosurgery https://pubmed.ncbi.nlm.nih.gov/31526671/
Hippocampal Avoidance Whole Brain Radiotherapy in Brain Metastasis Using Volumetric Modulated Arc Therapy: Experience From a Regional Cancer Centre of Eastern India https://pubmed.ncbi.nlm.nih.gov/37795235/
Leptomeningeal Metastases https://emedicine.medscape.com/article/1156338-overview
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis https://pubmed.ncbi.nlm.nih.gov/35802849/
A Phase I/II Study of Intrathecal Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive (HER2-Positive) Cancer With Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics https://pubmed.ncbi.nlm.nih.gov/35948282/
Tucatinib-Trastuzumab-Capecitabine for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: TBCRC049 Phase 2 Study Results https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2018
Radiological Response of Leptomeningeal Metastases According to Revised RANO Criteria Is Associated With Overall Survival in Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37243480/
-
Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic breast cancer, tackling curative intent, treatment duration, and the promise of emerging biomarkers.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001335. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
De Novo Oligometastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37607325/
A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30233772/
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) https://pubmed.ncbi.nlm.nih.gov/34995128/
Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer: A Retrospective Multicenter Study https://pubmed.ncbi.nlm.nih.gov/34778049/
NRG-BR002: A Phase IIR/III Trial of Standard of Care Systemic Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Resection (SR) for Newly Oligometastatic Breast Cancer (NCT02364557) https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1007
Systemic Therapies for HER2-Positive Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38201451/
Oligometastatic Breast Cancer and Metastasis-Directed Treatment: An Aggressive Multimodal Approach to Reach the Cure https://pubmed.ncbi.nlm.nih.gov/36950272/
Circulating Tumor Biomarkers in Early-Stage Breast Cancer: Characteristics, Detection, and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/37941557/
Minimal Residual Disease (MRD) Detection in Solid Tumors Using Circulating Tumor DNA: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/37636270/
-
Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/
T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy https://ascopost.com/news/june-2024/t-dxd-improves-progression-free-survival-in-patients-with-breast-cancer-previously-treated-with-endocrine-therapy/
Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/
-
Drs Kathy D. Miller and Sara M. Tolaney discuss advancements and considerations for optimizing treatment for HER2-positive breast cancer, focusing on balancing efficacy with minimizing toxicity.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001124. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/25564897/
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial https://pubmed.ncbi.nlm.nih.gov/36858723/
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30516102/
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34077270/
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT https://pubmed.ncbi.nlm.nih.gov/38935923/
Treatment Discontinuation, Patient-Reported Toxicities and Quality-of-Life by Age Following Trastuzumab Emtansine or Paclitaxel/Trastuzumab (ATEMPT) https://pubmed.ncbi.nlm.nih.gov/36450763/
ATEMPT 2.0: Adjuvant T-DM1 vs TH https://clinicaltrials.gov/study/NCT04893109
Neoadjuvant Treatment With HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/35158791/
5-Year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients With Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): A Multicentre, Open-Label, Phase 2 Randomised Trial https://pubmed.ncbi.nlm.nih.gov/27179402/
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy https://clinicaltrials.gov/study/NCT04266249
Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/
Incidence of Interstitial Lung Disease and Cardiotoxicity With Trastuzumab Deruxtecan in Breast Cancer Patients: A Systematic Review and Single-Arm Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/37481956/
STOP-HER2: Stopping Trastuzumab in HER2+ MBC https://clinicaltrials.gov/study/NCT05721248
